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The induction of an efficacious anti-tumor immune
response (IR) requires the cross-processing and presen-
tation of tumor antigen by Dendritic Cells (DCs). Block
of endocytated tumor associated antigen (TAA) in the
early compartments of the intracellular processing
machinery shifts the IR towards a Th2 balance. MUC1
is one of the most relevant tumor associated glycopro-
tein expressed by epithelial cells and its immunogenicity
is altered by the glycosylation profile. Moreover soluble
MUC1 antigen has shown to be stucked in endolysoso-
mal compartment of DCs thus inducing mostly a Th2
response. Objective of this study was to investigate
whether glycosylation pattern and MUC1 bound to
microvesicles could influence the antigen processing by
DCs. MUC1 as soluble molecule, independently by the
glycosylation profile, appears to be blocked in the pre-
endosomal compartment. Receptor-mediated endocyto-
sis pushes further the processing in the HLAII compart-
ment. Cross-processing of MUC1 in HLAI compartment
is observed only when MUC1 is carried by microvesicles
(MUC1-MVs). Moreover only DCs stimulated with
MUC1-MVs are able to induce IFN-g production by
MUC1 specific CD8+T cells. The distinct processing of
the MUC1 membrane bound is accompanied by degly-
cosylation processes thus generating Tn-MUC1 immu-
nogenic glycoforms. These results show that MUC1
undergoes to alternative processing pathways depending
by its form of release (MVs vs soluble) thus modifying
MUC1 immunogenicity. Moreover these experimental
evidence can be important to design efficacious glycoan-
tigen formulations for DC-based cancer vaccines.
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